

C¹ 1. (Twice Amended) A method for treating autoimmune demyelinating diseases which comprises administering to a patient in need thereof an effective amount of a Fas antagonist.

3. (Twice Amended) The method according to claim 1 wherein said Fas antagonist ~~is a~~ substance which suppresses Fas-Fas ligand binding.

C² 4. (Thrice Amended) The method according to claim 1 wherein said Fas antagonist is a polypeptide of (a) or (b) as follows:

(a) a polypeptide which comprises an amino acid sequence of a Fas protein that has been arbitrarily mutated at one or more amino acid residues by substitution, deletion and/or addition, and which has an activity of inhibiting Fas-mediated apoptosis;
or

(b) a fusion polypeptide comprising (a) and another polypeptide except (a).

5. (Thrice Amended) The method according to claim 1 wherein said Fas antagonist is an anti-Fas ligand antibody.